
|Videos|June 20, 2017
Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBC
Author(s)Sylvia Adams, MD
Sylvia Adams, MD, associate professor, Department of Medicine, NYU Langone Medical Center, discusses phase II results from cohort A of the KEYNOTE-086 trial, which explored pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer
2
Physical Activity: A Potential Pathway for Reducing Fatigue in Colorectal Cancer
3
mFOLFOX/Bevacizumab/Atezolizumab Improves PFS in dMMR/MSI-H Colorectal Cancer
4
Zoldonrasib Earns FDA Breakthrough Therapy Status in KRAS G12D-Mutant NSCLC
5















































